Podcasts about antibodies

Recorded October 31, 2025 In this episode of BioTalk Unzipped, Gregory Austin and Dr. Chad Briscoe sit down with Dr. Kate Neville, immunologist turned seasoned biotech patent attorney at Marshall, Gerstein & Borun, to unpack one of the most misunderstood and mission-critical areas of life sciences: intellectual property.If you are a biotech founder, scientist, executive, or investor, this conversation is essential listening.We explore what patent prosecution really means, when startups should begin thinking about IP protection, how “freedom to operate” can determine commercial viability, and how emerging AI tools are reshaping the patent landscape.Dr. Neville brings 25+ years of experience guiding university spin-outs, biotech startups, and global pharmaceutical companies through complex patent strategy. She has helped secure patents for FDA-approved drugs and offers a rare dual perspective as both scientist and attorney.In This Episode We Discuss:• The difference between patent prosecution and patent litigation• Why it is never too early for biotech startups to think about IP• The U.S. one-year grace period vs. Europe's stricter disclosure rules• What “Freedom to Operate” really means for commercialization• Antibody patents, CDR regions, and the doctrine of equivalents• How premature disclosure can impact global patent strategy• The real-world back-and-forth of patent office “office actions”• AI-assisted prior art search at the USPTO — opportunity or risk?• How funding cycles influence patent filing decisions• Women in biotech leadership and venture funding disparities• The most rewarding part of protecting life-changing therapiesWe also break down the USPTO's new AI pilot programs designed to modernize patent examination and discuss how artificial intelligence may impact biotech patenting over the next several years.Why This MattersIntellectual property is often the single most valuable asset in a biotech company.Strong IP strategy can unlock funding, partnerships, and market exclusivity.Weak or mistimed IP decisions can permanently limit global opportunity.For founders and scientists: timing, geography, and disclosure discipline matter more than most people realize.About Our GuestDr. Kate NevillePartner, Marshall, Gerstein & BorunPhD in Immunology, JDLinkedIn: https://www.linkedin.com/in/kate-neville-phd/Firm Bio: https://www.marshallip.com/katherine-l-neville-ph-d/Charity Highlight: Girls on the Run ChicagoAn organization building confidence and resilience in young girls through mentorship and athletic achievement.https://www.girlsontherun.org/HostsDr. Chad BriscoeBioanalytical Scientific Leaderhttps://www.linkedin.com/in/chadbriscoe/Gregory AustinDirector, Business Development | Bioanalysishttps://www.linkedin.com/in/gregoryaustin1/If you enjoyed this episode, subscribe to BioTalk Unzipped on Apple Podcasts, Spotify, or your preferred platform and share with a colleague in biotech, pharma, or life sciences innovation.

Thank you for joining us for our 2nd Cabral HouseCall of the weekend!   I'm looking forward to sharing with you some of our community's questions that have come in over the past few weeks…   Sami: Hi Dr. Cabral! I am currently doing your 21 day detox. I am loving every second of it. For one of my meals I decided to have red beats as my carb/veggie. I had this for two dinner meals in a row and noticed the redness in my stool showed up the next morning after my second meal and then 48 hours after my second meal. I read online that eating red beats can help display gut transit time. I know red beats normally turn your stool a red/pink color in general. Are red beats a good natural/home remedy to decide gut transit time? Or would something like the blue poop test work best?                                              Larissa: Hello! My patient recently tested positive for EBV VCA IgM antibodies with positive EBV IgG antibodies but negative early EBV antigen and EBNA levels. She is experiencing fatigue. Would you consider this an acute or reactivated infection? Could it be a false positive? Would you treat this? Thank you in advance!      Katrina: As I explore your protocol options and tests, how would having gastric bypass, 22 years ago affect the results to achieve optimal health. Will the products be effective due to potential absorption issues?     Ateba: Hello Dr.Cabral, I've had some bony growth behind my teeth over the last decade. I believe it's called Mandibular Tori. It seems to have grown quite a bit the last few years. My dentist says it's from jaw clenching, which I had during sleep for quite some time, but I've also heard other things (nutrition deficiencies/toxicity's etc). Don't have parasites according to my stool test, just excessive stress. Wondering if you have any recommendations for this condition. God Bless.      Lisa: Hi Dr Cabral! I listen to you daily, thank you for your knowledge and swear by your functional detox a few times a year! I have been waking up recently (about the last year now) with a mouth full of saliva and I'm forced to get up to spit. I sleep really well - straight through the night, yet this is a bit concerning to me. Any ideas?    Thank you for tuning into this weekend's Cabral HouseCalls and be sure to check back tomorrow for our Mindset & Motivation Monday show to get your week started off right! - - - Show Notes and Resources: StephenCabral.com/3663 - - - Get a FREE Copy of Dr. Cabral's Book: The Rain Barrel Effect - - - Join the Community & Get Your Questions Answered: CabralSupportGroup.com - - - Dr. Cabral's Most Popular At-Home Lab Tests: > Complete Minerals & Metals Test (Test for mineral imbalances & heavy metal toxicity) - - - > Complete Candida, Metabolic & Vitamins Test (Test for 75 biomarkers including yeast & bacterial gut overgrowth, as well as vitamin levels) - - - > Complete Stress, Mood & Metabolism Test (Discover your complete thyroid, adrenal, hormone, vitamin D & insulin levels) - - - > Complete Food Sensitivity Test (Find out your hidden food sensitivities) - - - > Complete Omega-3 & Inflammation Test (Discover your levels of inflammation related to your omega-6 to omega-3 levels) - - - Get Your Question Answered On An Upcoming HouseCall: StephenCabral.com/askcabral - - - Would You Take 30 Seconds To Rate & Review The Cabral Concept? The best way to help me spread our mission of true natural health is to pass on the good word, and I read and appreciate every review!  

This week, we discuss a new antibody-based nasal spray that protects against the flu: how does it work? Plus, the tiny self-replicating molecule that may give clues to the origins of life on Earth, whether we should regulate "mirror life" research, and how bacteria protect oak trees from drought and other stresses... Like this podcast? Please help us by supporting the Naked Scientists

During last year's PEGS Europe, industry experts gathered on a panel to discuss the future of biologic therapeutics. The panel kicked off with a presentation on 50 years of monoclonals, from hybridomas to next-gen antibody therapeutics, followed by a conversation featuring Paul Carter, Ph.D., Genentech Fellow of Antibody Engineering, G. Jonah Rainey, Ph.D., associate vice president of Eli Lilly and Company, and Janine Schuurman, Ph.D., biotech consultant at Lust for Life Science B.V. Moderated by Daniel Chen, M.D., Ph.D., founder and CEO of Synthetic Design Lab, the discussion centered around whether half-life extended peptides will eventually replace multispecific antibodies. Links from this episode:  PEGS Europe  PEGS Synthetic Design Lab Genentech Eli Lilly and CompanyLust for Life Science B.V. 

Featuring a slide presentation and related discussion from Dr Kathleen N Moore, including the following topics: Overview of developments and opportunities with antibody-drug conjugates (ADCs) in ovarian cancer(0:00) Targeting folate receptor alpha with mirvetuximab soravtansine (3:59) Targeting TROP2 with ADCs (9:12) Targeting folate receptor alpha with ADCs (14:17) Targeting cadherin-6 with ADCs (17:27) Targeting HER2 with ADCs (26:12) Potential of ADCs in the treatment of platinum-sensitive ovarian cancer (28:38)  CME information and select publications

Featuring an interview with Dr Kathleen N Moore, including the following topics: Overview of the mechanism of action and pharmacology of antibody-drug conjugates (ADCs) (0:00) Comparing toxicities of conventional chemotherapy and ADCs (6:26) Potential of ADCs as maintenance therapy for ovarian cancer (11:35) Treatment based on platinum sensitivity and homologous recombination-deficiency status (15:10) Case: A woman in her mid 70s presenting with Stage IV ovarian cancer receives raludotatug deruxtecan (18:46) Case: A woman in her mid 60s with relapsed/refractory ovarian cancer receives mirvetuximab soravtansine (41:22) Case: A woman in her early 70s with relapsed/refractory ovarian cancer receives multiple ADCs in clinical trials (45:57) CME information and select publications

Dr Kathleen N Moore from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on available and novel treatment strategies with antibody-drug conjugates for ovarian cancer.CME information and select publications here.

Why do so many people still feel hypothyroid when their labs look "normal"? In this episode of Thyroid Answers, Dr. Eric Balcavage completes the thyroid lab conversation by addressing three of the most misunderstood tests in thyroid care: reverse T3, T3 uptake, and thyroid antibodies. You'll learn: What reverse T3 actually represents—and why it rises or falls Why high reverse T3 does not mean blocked T3 receptors How T3 medication lowers reverse T3 by suppressing T4, not by improving physiology What the T3 uptake test measures and why it still matters Why free T4 and free T3 can be misleading without total hormone levels How binding proteins, estrogen, liver function, inflammation, and medications affect interpretation What thyroid antibodies do—and do not—tell us about thyroid damage and disease activity This episode is essential listening if you've been told your thyroid is "optimized," yet symptoms persist—or if you're trying to understand why thyroid medications work for some people and cause instability for others. This discussion sets the stage for the February series on thyroid medication physiology, including T4-only therapy, T3 therapy, combination therapy, and desiccated thyroid.

Thyroid issues can feel confusing — especially when you're told your TSH is “off,” you have antibodies, or you're prescribed medication without fully understanding what's going on. The Lanby's Dr. Stephanie Wallman, Medical Director, breaks down what thyroid dysfunction actually means, how to interpret your labs, and how to support your thyroid with a root-cause, whole-body approach.On this “One Take on One Take” episode:Tip 1: Understand what your TSH, Free T3, Free T4, and thyroid antibodies really mean — and why TSH alone doesn't tell the full story.Tip 2: Learn how gluten, iodine imbalance, stress, and toxin exposure can trigger or worsen thyroid dysfunction and autoimmune thyroid conditions.Tip 3: Know when lifestyle, nutrition, and stress optimization are enough — and when thyroid medication like Synthroid may be appropriate as part of comprehensive care.Subscribe to Get Well Better by The Lanby: Apple Podcasts: https://podcasts.apple.com/us/podcast/get-well-better Spotify: https://open.spotify.com/show/get-well-better YouTube: @TheLanby Or search “Get Well Better by The Lanby” on your favorite podcast platform!VISIT THE LANBY: Explore membership and learn more about The Lanby's functional medicine approach:https://www.thelanby.comFOLLOW THE LANBY ON SOCIAL: Instagram: https://www.instagram.com/thelanby Tiktok: https://www.tiktok.com/@thelanby LinkedIn: https://www.linkedin.com/company/thelanbySTAY IN THE KNOW: Subscribe to The Lanby newsletter for health tips, podcast drops, and expert insights: https://www.thelanby.com/newsletter

Send us a textJoin us for Part 2 of our Metastatic Endometrial Cancer special with the amazing Dr Gemma Eminowicz from University College London Hospital. In episode 1 we looked at molecular profiling and immunotherapy.In this episode we explore the role of;- hormone therapy- Antibody drug conjugates- PARP inhibitorsEndometrial cancer is taking off in terms of new and exciting treatment options.Gemma does an amazing job talking us through them.Enjoy.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we'll delve into the multitude of changes and advancements sweeping across the industry, each with profound implications for drug development, patient care, and market dynamics.The pharmaceutical landscape continues to transform as companies like Daiichi Sankyo make significant progress with antibody-drug conjugates (ADCs). Their collaboration with AstraZeneca on products like Enhertu and Datroway represents a robust push into earlier lines of therapy. This strategic move aligns with a broader industry trend where ADCs are being positioned as front-line oncology treatments. These therapies are lauded for their targeted delivery mechanisms that maximize therapeutic efficacy while minimizing off-target effects. However, the competitive landscape is becoming increasingly fierce, necessitating robust clinical data to stand out in this rapidly evolving market segment.Elsewhere, Moderna's recent decision to pause new late-stage trials for infectious disease vaccines highlights the intricate interplay between public sentiment and corporate strategy. The rising anti-vaccine sentiment in the U.S., compounded by diminishing support infrastructure from previous administrations, has significantly influenced Moderna's strategic recalibration. This situation underscores a critical challenge for developers of mRNA platforms: how to navigate complex public perceptions and policy landscapes while pushing forward with vaccine innovations.From a regulatory perspective, Recipharm's commissioning of a new facility in Bengaluru, India for non-bacterial beta-lactam drugs aligns with evolving FDA standards. This investment is not just about compliance; it's a proactive adaptation to meet rising customer demand and represents a strategic partnership with a major biopharmaceutical player. Such collaborations are crucial as they help scale drug production capabilities effectively.The dissolution of the marketing partnership between Arcutis and Kowa over Zoryve reflects the ever-dynamic nature of commercial collaborations within the industry. Originally intended to broaden Zoryve's market beyond dermatologists to include primary care physicians, this shift may indicate strategic realignments or divergent priorities between partners. Such changes can significantly impact market penetration strategies and highlight the importance of aligned goals within partnerships.In Europe, regulatory expansion by GSK of its Arexvy vaccine for all adults marks a pivotal milestone in widening access to crucial vaccines. This development not only enhances GSK's market presence but also underscores the agility required in regulatory responses to public health needs.On the financial front, settlements under the False Claims Act reaching $6.8 billion in FY2025 demonstrate heightened scrutiny on compliance practices within the industry. This serves as a stark reminder of both financial and reputational risks tied to non-compliance and underscores an ongoing need for stringent oversight mechanisms.Amidst economic uncertainties, AstraZeneca's decision to pause its UK research site investment reflects broader industry challenges related to strategic reallocations of resources. Companies are increasingly re-evaluating their geographic footprints and investment priorities in response to evolving market conditions.In precision oncology, Guardant Health's FDA approval for its Guardant360 CDx test in conjunction with Pfizer's Braftovi highlights how companion diagnostics are becoming integral in enhancing therapeutic outcomes through tailoring treatments based on specific genetic profiles. These developments illustrate a multifaceted landscape where scientific innovation, regulatory changes, strategic partnerships, and compliance considerations converge.The recent landscapSupport the show

In this episode, we review the high-yield topic of⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) ⁠⁠⁠ from the Immunology section.Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbullets

Featuring perspectives from Prof Michael Dickinson and Dr Laurie H Sehn, including the following topics:  Introduction (0:00) Future Treatment of Non-Hodgkin Lymphoma (NHL) (2:24) Case: A man in his mid 60s with diffuse large B-cell lymphoma (DLBCL) and early relapse on axicabtagene ciloleucel receives glofitamab — Dr Sehn (8:10) Case: A man in his late 60s with Type 2 diabetes, congestive heart failure and chronic obstructive pulmonary disease receives glofitamab monotherapy after glofitamab with gemcitabine/oxaliplatin for relapsed GCB-type double-hit DLBCL — Matthew Lunning, DO (14:54) Practical Perspectives on the Current Role of Bispecific Antibodies in the Management of Lymphoma — Prof Dickinson (18:00) Case: A woman in her mid 50s with multiregimen-recurrent follicular lymphoma (FL) receives mosunetuzumab — Carla Casulo, MD (35:33) Case: A man in his late 70s with multiregimen-refractory FL receives mosunetuzumab with an ongoing complete response — Dr Sehn (40:05) FL and Other NHL Subtypes — Dr Sehn (45:30) CME information and select publications

Prof Michael Dickinson from Peter MacCallum Cancer Centre in Melbourne, Australia, and Dr Laurie H Sehn from the University of British Columbia in Vancouver, Canada, discuss clinical cases and recent findings from the 2025 ASH Annual Meeting relating to the use of bispecific antibodies in the management of lymphoma.CME information and select publications here.

If you've ever wondered whether your thyroid questions are too specific or if anyone else is dealing with the same confusion this episode is for you.In this Q&A episode, I answer a mix of situational and common thyroid health questions submitted by listeners with Graves', Hashimoto's, and other thyroid conditions. We cover topics like thyroid antibodies, lab interpretation, medication decisions, iodine, fatigue, hair loss, nodules, and lifestyle factors such as fasting and gut health. Some questions are very individual, while others apply broadly and can help you better understand your own labs and symptoms. My goal is to give you context not one-size-fits-all answers, so you can make more informed decisions about your next steps.If you've been asking yourself, “Does this apply to me?” or “Why hasn't this been explained clearly before?”, tune in and see which of these questions helps bring clarity to your own thyroid journey.Episode Timeline: 00:04 – Episode Overview 01:40 – Antibodies and Thyroid Eye Disease03:35 – T3 vs T4 Medications05:45 – Hyperthyroidism vs Graves Disease07:05 – When Thyroid Meds Don't Help09:09 – Fluctuating Hyper and Hypo Labs11:40 – Hyperparathyroidism and Surgery Questions15:55 – Thyroid Ablation: Risk vs Benefit18:32 – What Triggers Graves Disease22:10 – Iodine: Helpful or Harmful?26:10 – Hair Loss and Thyroid Imbalance27:34 – Preventing Postpartum Thyroiditis30:10 – Intermittent Fasting and Thyroid Health33:00 – Gut Testing: Is It Worth It?36:30 – Thyroid Nodules and Treatment Options40:15 – High Cholesterol and Thyroid Issues42:40 – Can You Stop Thyroid Medication?45:10 – Normal TSH, Still SymptomaticTo take the Save My Thyroid Quiz visit www.savemythyroid.com/quiz Free resources for your thyroid healthGet your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.comHigh-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' s Have you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid?Get free access to hundreds of articles and blog posts: https://www.naturalendocrinesolutions.com/articles/all-other-articles Watch Dr. Eric's YouTube channel: https://www.youtube.com/c/NaturalThyroidDoctor/videos Join Dr. Eric's Graves' disease and Hashimoto's group: https://www.facebook.com/groups/saveyourthyroid Take the Thyroid Saving Score Quiz: https://quiz.savemythyroidquiz.com/sf/237dc308 Read all of Dr. Eric's published books: http://savemythyroid.com/thyroidbooks Work with Dr. Eric: https://savemythyroid.com/work-with-dr-eric/

Communion After Dark - features the latest and best in Dark Alternative-Electronic Music. This week's show features music from Lord of the Lost, Ladytron, Antibody, Grendel, BlakLight, Dulce Liquido, and many more artists from around the world. 

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH information, and to apply for credit, please visit us at PeerView.com/AEN865. CME/MOC/EBAH credit will be available until January 4, 2027.Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Lymphoblastic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH information, and to apply for credit, please visit us at PeerView.com/AEN865. CME/MOC/EBAH credit will be available until January 4, 2027.Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Lymphoblastic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH information, and to apply for credit, please visit us at PeerView.com/AEN865. CME/MOC/EBAH credit will be available until January 4, 2027.Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Lymphoblastic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

This is the latest episode of the free DDW Narrated Podcast. The episode covers two articles written for DDW Volume 25, Issue 2, Spring 2024. The first article is called 'Machine learning: developing next generation antibody therapeutics'. Ben Holland, CTO and Co-Founder of Antiverse, discusses how artificial intelligence and machine learning are benefitting antibody discovery and design. The second article is called 'The next generation of AI'. In the piece, DDW Editor Reece Armstrong speaks to Sean McClain, Founder & CEO of Absci, about the rise of generative AI in life sciences. You can listen below, or find The Drug Discovery World Podcast on Spotify, Google Play and Apple Podcasts.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH information, and to apply for credit, please visit us at PeerView.com/AEN865. CME/MOC/EBAH credit will be available until January 4, 2027.Moving Forward in B-ALL: Insights on Modern and Emerging Standards With Off-the-Shelf Bispecific Antibodies In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Acute Lymphoblastic Leukemia. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent educational grant from AstraZeneca.Disclosure information is available at the beginning of the video presentation.

Antibody therapeutics have transformed modern medicine, but for many scientists, developing new candidates still feels like searching for a needle in a haystack—a slow, expensive, and unpredictable process. Structural biology and high-throughput data generation are now collapsing that haystack, offering unprecedented visibility into the molecular handshake that drives life: protein-protein interactions.In this episode, David Brühlmann sits down with Troy Lionberger, Chief Business Officer at A-Alpha Bio, for an in-depth discussion on protein-protein interactions and how advances in data generation and machine learning are transforming antibody discovery and drug development.Troy Lionberger shares his journey into biotechnology, challenges long-held beliefs about antibody development, and explains how Alphabio's high-throughput affinity measurements are shortening timelines and improving outcomes for therapeutic development.In this episode, you'll learn about:The historical and current challenges in characterizing these interactions at scale (06:22)How new technologies—especially high-throughput platforms—are changing the needle-in-the-haystack approach (08:40)A comparison of traditional in vivo and in vitro antibody discovery methods, along with their strengths and limitations (09:06)The evolving role of AI and machine learning in antibody discovery and lead optimization (12:11)Real-world examples of how A-Alpha Bio's approach is compressing years of work into months without sacrificing quality (13:58)The science behind A-Alpha Bio's AlphaSeq technology and how it leverages yeast display and genomics for large-scale affinity measurements (20:43)The practical affinity range the technology can measure, covering most therapeutic applications (23:25)Whether you're a scientist navigating CMC or a biotech professional curious about next-generation workflows, this episode offers practical insights into both traditional and emerging methodologies in the field.Connect with Troy Lionberger:LinkedIn: www.linkedin.com/in/troylionbergerA-Alpha Bio website: www.aalphabio.comNext step:Need fast CMC guidance? → Get rapid CMC decision support hereOne bad CDMO decision can cost you two years and your Series A. If you're navigating tech transfer, CDMO selection, or IND prep, let's talk before it gets expensive. Two slots open this month.Support the show

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/YAZ865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Non-Hodgkin Lymphoma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/YAZ865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Non-Hodgkin Lymphoma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/YAZ865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Non-Hodgkin Lymphoma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

It's New Tunesday: new releases from the past week! Give the bands a listen. If you like what you hear, support the bands! Today's episode features new releases by Ironic Sweden, Mesh, Lifelong Corporation, Analog 80, Ceremony Shadows, Antibody, CK 37, Bionic Bitch, Sarin, Nova State Machine, FEVR, Coloured Tears, Affet Robot, Sonic Thing, and Lord Of The Lost!

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/YAZ865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Non-Hodgkin Lymphoma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/YAZ865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Non-Hodgkin Lymphoma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/EBAH/AAPA information, and to apply for credit, please visit us at PeerView.com/YAZ865. CME/MOC/EBAH/AAPA credit will be available until January 4, 2027.Off the Shelf and in the Clinic for NHL: Leveraging Bispecific Antibody Strategies in DLBCL, FL, and Beyond In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and HealthTree Foundation for Non-Hodgkin Lymphoma. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca and Regeneron Pharmaceuticals, Inc.Disclosure information is available at the beginning of the video presentation.

Featuring perspectives from Dr Javier Cortés, Dr Rita Nanda, Prof Peter Schmid and Dr Priyanka Sharma, including the following topics:  Introduction (0:00) Case: A woman in her early 80s with multiple comorbidities and triple-negative breast cancer (TNBC) develops bone-only metastases 4 months after declining capecitabine for post-neoadjuvant residual disease — Justin Favaro, MD, PhD (1:50) Case: A woman in her mid 70s with ER-negative, HER2-low (IHC 1+), PIK3CA-mutated, PD-L1-positive metastatic breast cancer (mBC) after receiving 3 cycles of neoadjuvant paclitaxel/carboplatin/pembrolizumab, which was discontinued — Alan Astrow, MD (6:47) Previously Untreated Metastatic TNBC (mTNBC) — Prof Schmid (10:47)  Case: A woman in her early 80s with multiregimen-recurrent ER-positive, HER2-low (IHC 1+) ESR1-mutant mBC receives sacituzumab govitecan — Jennifer Yannucci, MD (27:19) Case: The role of datopotamab deruxtecan (Dato-DXd) for patients with ER-positive, HER2-low mBC who experienced disease progression on prior trastuzumab deruxtecan (T-DXd) — Ranju Gupta, MD; Case: A woman in her late 70s with bilateral recurrence in the lungs of ER-negative, HER2-low (IHC 1+) breast cancer (PD-L1 TPS 20%) receives Dato-DXd with durvalumab on protocol — Yanjun Ma, MD, PhD (31:35) Integrating Antibody-Drug Conjugates (ADCs) into the Management of Endocrine-Resistant Hormone Receptor-Positive mBC — Dr Sharma (36:31) Case: A woman in her early 70s with recurrent ER-negative, HER2-low (IHC 2+) mBC receives sacituzumab govitecan and achieves complete remission — Dr Gupta; Case: Management of neutropenia associated with sacituzumab govitecan — Gigi Chen, MD (50:30) Case: A woman in her late 60s with recurrent ER-negative, HER2-low (IHC 1+) mBC (HER2 V69L mutation) receives T-DXd and achieves a complete response but develops Grade 1 interstitial lung disease — Dr Gupta; Case: Management of T-DXd-related side effects — Laila Agrawal, MD (54:10) Selection and Sequencing of Therapy for Relapsed/Refractory mTNBC — Dr Nanda (58:59) Case: A woman in her early 40s with multiregimen-recurrent ER-positive, HER2-low mBC who has experienced severe nausea with past treatments is about to initiate T-DXd — Atif M Hussein, MD, MMM (1:12:40) Tolerability and Other Practical Considerations with ADCs and Other Cytotoxic Agents for mBC — Dr Cortés (1:18:10) CME information and select publications

Dr Javier Cortés from the International Breast Cancer Center in Barcelona, Spain, Dr Rita Nanda from the University of Chicago, Prof Peter Schmid from Barts Cancer Institute in London, United Kingdom, and Dr Priyanka Sharma from the University of Kansas Cancer Center in Westwood discuss key clinical data with antibody-drug conjugates for metastatic breast cancer and their expert perspectives surrounding its clinical applications.CME information and select publications here.

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

Rebecca Dent, MD, FRCP (Canada) - TROP2 and Triple-Negative Breast Cancer: The Rationale and Emerging Evidence for Exploring the Therapeutic Potential of TROP2-Targeted Antibody-Drug Conjugates in Earlier Lines and Disease-Stage Settings

Let's take a moment to be in awe of breastmilk

In a special cobranded episode between Oncology On the Go and the American Society for Transplantation and Cellular Therapy (ASTCT)'s program ASTCT Talks, Rahul Banerjee, MD, FACP, a physician-researcher who specializes in multiple myeloma at Fred Hutchinson Cancer Center, and Brooke Adams, PharmD, BCOP, a clinical pharmacist and transplant specialist at Orlando Health, break down practice‑changing data in multiple myeloma from the ASH Annual Meeting.The experts focus on bispecific antibodies and BCMA CAR T-cell therapies and close the discussion by reflecting on how data is redefining the treatment paradigm in multiple myeloma, raising possibilities of deep MRD negativity, treatment de-escalation, and prolonged drug holidays. Listen below or via your favorite podcast platform.

Reagan Badger, Susan L Fink, Kathleen Hutchinson, Mark H Wener, Chihiro Morishima, Rebecca S Treger. Concurrent Anti-PR3 Immunoassay and cANCA Indirect Immunofluorescence Testing Provide Complementary Information for Clinical Laboratory Detection of Antineutrophil Cytoplasmic Antibodies. The Journal of Applied Laboratory Medicine, Volume 11, Issue 1, January 2026, Pages 83–97. https://doi.org/10.1093/jalm/jfaf168

Featuring perspectives from Dr Lisa A Carey and Dr Rita Nanda, including the following topics:  Overview: Molecular basis of antibody-drug conjugate (ADC) toxicities — Sequencing of ADCs and mechanisms of resistance (0:00) Case: A woman in her late 60s with localized triple-negative breast cancer develops myocarditis during neoadjuvant therapy with chemotherapy/pembrolizumab — Richard Zelkowitz, MD (8:22) Case: A woman in her mid 70s with recurrent ER-negative, HER2-low, PD-L1-positive metastatic breast cancer (mBC) who experiences disease progression on nab paclitaxel/atezolizumab responds to sacituzumab govitecan — Ranju Gupta, MD (26:43) Case: A woman in her early 80s with recurrent ER-positive, HER2-low (IHC 1+) mBC experiences disease progression on trastuzumab deruxtecan (T-DXd), then receives datopotamab deruxtecan and develops pulmonary symptoms — Laila Agrawal, MD (32:11) Data Review: T-DXd (37:51) Case: A woman in her early 70s with recurrent ER-positive, HER2-low (IHC 1+) mBC, including bladder metastases, experiences disease progression after palbociclib/letrozole, then capivasertib/fulvestrant, then nab paclitaxel — Justin Favaro, MD, PhD (44:02) Case: A woman in her late 70s with ER-positive, HER2-low mBC who experiences disease progression after 1 year of ribociclib/letrozole receives sacituzumab govitecan — Erik Rupard, MD (55:19) CME information and select publications

Dr Lisa A Carey from the UNC Lineberger Comprehensive Cancer Center in Chapel Hill, North Carolina, and Dr Rita Nanda from The University of Chicago in Illinois engage in an evidence-based discussion around real-world cases involving common toxicities associated with antibody-drug conjugates in the management of breast cancer.CME information and select publications here.

In this episode, we're revisiting some of the most magical moments and scientific milestones of 2025 - including the incredible legacy of Dame Jane Goodall, the brain-wave reading bionic-knee, why labradors are so greedy, and the beer that doesn't give you a hangover... Like this podcast? Please help us by supporting the Naked Scientists

In this episode of Tiny Show and Tell Us, we read an email from “baby sis” aka Binky aka Sam's younger sister Caroline who writes in about an alarming pregnancy test that predates today's at-home tests. Then we talk about a fascinating study that found a dead salmon showed brain activity in an MRI machine. Spoiler: It wasn't actually alive, scientists just really needed to rethink MRI analysis. We need your stories — they're what make these bonus episodes possible! Write in to tinymatters@acs.org *or fill out this form* with your favorite science fact or science news story for a chance to be featured.A transcript and references for this episode can be found at acs.org/tinymatters.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

JHLT: The Podcast returns with an episode discussing the paper, "High Antiphospholipid Antibody Titers and Outcomes of Pulmonary Endarterectomy: A Single-Center Retrospective Observational Cohort Study," from the December issue of JHLT.   They are joined by the first author, Camille Miard, MD, and senior author, François Stéphan, MD, PhD, both from the cardiothoracic intensive care unit at Hôpital Marie Lannelongue in Paris.   The discussion explores: Whether antiphospholipid antibody titers could predict postoperative outcomes for CTEPH patients undergoing pulmonary endarterectomy (PEA) How APS patients differed from non-APS patients in the PEA cohort The changes in clinical practice at Marie Lannelongue after the study's findings   For the latest studies from JHLT, visit www.jhltonline.org/current, or, if you're an ISHLT member, access your Journal membership at www.ishlt.org/jhlt.   Don't already get the Journal and want to read along? Join the International Society of Heart and Lung Transplantation at www.ishlt.org for a free subscription, or subscribe today at www.jhltonline.org.

In this episode of the Oncology Brothers podcast, we dived deep into the world of antibody drug conjugates (ADCs) in non-small cell lung cancer (NSCLC). We welcomed Dr. Jacob Sands from the Dana-Farber Cancer Institute to discuss the latest ADCs approved for NSCLC, including Trastuzumab deruxtecan (TDXd), Datopotamab deruxtecan (Dato-DXd), and Telisotuzumab Vedotin (Teliso-V). We explored the side effect profiles of these therapies, focusing on critical toxicities such as interstitial lung disease (ILD), mucositis, and peripheral neuropathy. Dr. Sands shared valuable clinical pearls on managing these adverse events, emphasized the importance of proactive monitoring and patient education. Key topics covered in this episode: • Overview of ADCs and their role in NSCLC treatment • TDXd: alopecia, ILD, fatigue, nausea/vomiting • Dato-DXd:  cytopenias, mucositis, dry eyes • Teliso-V: peripheral neuropathy, fatigue, peripheral edema • The evolving landscape of ADCs and future directions in lung cancer treatment Whether you're a healthcare professional or someone interested in oncology, this episode provides essential insights into the management of side effects associated with these innovative therapies. Tune in for practical advice and expert opinions that can enhance patient care in the community setting. Follow us on social media: •⁠  ⁠X/Twitter: https://twitter.com/oncbrothers •⁠  ⁠Instagram: https://www.instagram.com/oncbrothers •⁠  Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more episodes on practice-changing discussions in oncology! #ADC #NSCLC #TDXd #DatoDXD #TelisoV #ToxicityManagement #OncologyBrothers

"I'll go back to the backpack analogy. When your kids come home with a backpack, all of a sudden their homework is not on the desk where it's supposed to be. It's in the kitchen; it kind of spreads all over the place, but it's still in the house. When we give antibody–drug conjugates (ADCs), the chemotherapy does go in, but then it can kind of permeate out of the cell membrane and something right next to it—another cancer cell that might not look exactly like the cancer cell that the chemotherapy was delivered into—is affected and the chemotherapy goes over to that cancer cell and kills it," ONS member Marisha Pasteris, OCN®, office practice nurse in the breast medicine service at Memorial Sloan Kettering Cancer Center in New York, NY, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about ADCs in metastatic breast cancer. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  This podcast is sponsored by Gilead and is not eligible for NCPD contact hours. ONS is solely responsible for the criteria, objectives, content, quality, and scientific integrity of its programs and publications.  Episode Notes  This episode is not eligible for NCPD. ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 378: Considerations for Adolescent and Young Adult Patients With Metastatic Breast Cancer Episode 368: Best Practices for Challenging Patient Conversations in Metastatic Breast Cancer Episode 350: Breast Cancer Treatment Considerations for Nurses Episode 303: Cancer Symptom Management Basics: Ocular Toxicities ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Black Patients With Metastatic Breast Cancer Are Less Informed About Their Clinical Trial Options Communication Case Study: Talking to Patients About Progressive Metastatic Breast Cancer What Is HER2-Low Breast Cancer? ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin-ejfv Fam-trastuzumab deruxtecan-nxki ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Breast Care for Oncology Nurses Guide to Cancer Immunotherapy (second edition) ONS courses: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing article: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care The Association Between Hormone Receptor Status and End-of-Life Care Among Patients With Metastatic Breast Cancer Oncology Nursing Forum article: Impact of Race and Area Deprivation on Triple-Negative Metastatic Breast Cancer Outcomes ONS huddle cards: Altered Body Image Huddle Card Chemotherapy Huddle Card Targeted Therapy Huddle Card Foundations of Antibody–Drug Conjugate Use in Metastatic Breast Cancer: A Case Study ONS Biomarker Database (refine by breast cancer) ONS Breast Cancer Learning Library American Society of Clinical Oncology (ASCO) homepage Drugs@FDA package inserts National Comprehensive Cancer Network homepage Susan G. Komen metastatic breast cancer page To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "What an ADC is doing is taking the antibody and linking it to a cytotoxic chemotherapy with the idea of delivering it directly into the cell. How I explain this to new nurses or patients is a backpack analogy. If we think of it as a HER2 molecule wearing a chemo backpack, it's going to find the HER2 receptor attached to it and then drop the chemotherapy into the cell via the backpack. Similar to how we come home from work, we open the key to our door, we're carrying all of our items, and then we drop our own personal items in our house." TS 2:30 "The reason that so many patients with metastatic breast cancer are able to receive ADC therapy is because they are targeting two very common antibodies that we see in breast cancer. One is HER2 and the other is trophoblast cell surface antigen 2 (TROP2). These are seen across the board. We see these on triple-negative breast cancers, hormone receptor–positive cancers, and HER2-positive breast cancers. And now we have a new way to talk about HER2, which is a HER2-low. ... Recently, we have found that patients who express low levels of HER2 are able to receive ADC therapy, specifically fam-trastuzumab deruxtecan." TS 4:21 "Another [ADC] that has just been approved is datopotamab deruxtecan. This is another ADC that targets the TROP2 receptor on a cancer cell. This one carries a lot of side effects. I mentioned earlier that you need an ophthalmology clearance because there is a lot of ocular toxicity around this one. We see a lot of blepharitis, conjunctivitis, there can be blurred vision. Another thing we monitor on this one is mucositis. In the package insert, there's a recommendation for using ice chips while receiving the treatment. ... Then in the HER2-positive and HER2-low space is the big one, which is fam-trastuzumab deruxtecan. This was approved in 2019 for the HER2-positive patients, then more recently in the HER2-low [patients]. The big [side effect] with this one is interstitial lung disease." TS 10:11 "Interstitial lung disease is an inflammation or a little bit of fibrosis within the lung that causes an impaired exchange between the oxygen and carbon dioxide. This was seen in the clinical trials, specifically around fam-trastuzumab deruxtecan. During the trials, they had a very small percentage, I think it was 1%, that died due to interstitial lung disease. So, this is a very important side effect for us as nurses to be aware of. It typically presents in patients like a dyspnea. A lot of times, it's like, 'Well, I used to be able to walk my kid to the bus stop, but now when I walk there, I feel really short of breath.' Or 'I've had this dry cough for the past couple weeks and I've tried medications, but haven't had that relieved.' So, we really need to be aware of that because early intervention in interstitial lung disease is key." TS 12:57 "ADCs are toxic drugs. They have the benefit of being targeted, but we know that they carry a lot of side effects. ... Their specificity makes them so wonderful and we've seen amazing responses to these drugs. But also, we want patients to be safe. We want to give these drugs safely. So, we have to assess our patients and make sure that this is an appropriate patient to give this therapy to. I think that's an open conversation that clinicians need to have with patients regarding these drugs." TS 18:08

The path to lowering antibodies isn't always quick, but it becomes clearer once you know which five areas matter most.In this conversation, I walk through what thyroid antibodies actually mean and why they can fluctuate from one test to the next. I then break down five approaches that consistently make a difference, strengthening the foundations of health, addressing personal triggers, supporting gut health, reducing oxidative stress, and understanding when something like Low-Dose Naltrexone (LDN) might play a role. The goal is to help you see where your efforts matter most and why a layered approach usually works better than relying on a single strategy.If you've been trying to make sense of your antibodies or you're looking for next steps, you'll find this episode helpful to listen to.Episode Timeline: 00:00 — What Thyroid Antibodies Are01:15 — Types of Graves' Antibodies03:45 — Why Antibodies Fluctuate05:10 — Way #1: Foundations First08:20 — Foods & Common Triggers10:45 — Stress, Toxins, Infections12:50 — Way #2: Remove Triggers14:05 — Way #3: Heal the Gut16:40 — Way #4: Reduce Oxidative Stress18:30 — Supplements for Antibody Support19:45 — Way #5: Low-Dose Naltrexone21:10 — Summary of All Five Steps22:00 — Invitation to Free ChallengeTo take the Save My Thyroid Quiz visit www.savemythyroid.com/quiz Free resources for your thyroid health Get your FREE Thyroid and Immune Health Restoration Action Points Checklist at SaveMyThyroidChecklist.com High-Quality Nutritional Supplements For Hyperthyroidism and Hashimoto' s Have you checked out my new ThyroSave supplement line? These high-quality supplements can benefit those with hyperthyroidism and Hashimoto's, and you can receive special offers, along with 10% off your first order, by signing up for emails and text messages when you visit ThyroSave.com. Do You Want Help Saving Your Thyroid? Get free access to hundreds of articles and blog posts: https://www.naturalendocrinesolutions.com/articles/all-other-articles Watch Dr. Eric's YouTube channel: https://www.youtube.com/c/NaturalThyroidDoctor/videos Join Dr. Eric's Graves' disease and Hashimoto's group: https://www.facebook.com/groups/saveyourthyroid Take the Thyroid Saving Score Quiz: https://quiz.savemythyroidquiz.com/sf/237dc308 ...

Please visit answersincme.com/860/99224979-replay1 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, experts in oncology discuss the latest data on emerging B7-H3–directed antibody–drug conjugates (ADCs) for the treatment previously treated extensive-stage small-cell lung cancer (ES-SCLC). Upon completion of this activity, participants should be better able to: Specify how B7-H3 overexpression is relevant to ES-SCLC prognosis and treatment; Interpret the clinical evidence for emerging B7H3–directed ADCs in patients with previously treated ES-SCLC; and Translate current evidence and clinical considerations for B7-H3–targeted ADCs into treatment algorithms for patients with ES-SCLC.

"Antibody–drug conjugates (ADCs) have three basic parts: the antibody part, the cytotoxic chemo, and the linker that connects the two. First, the antibody part binds to the target on the surface of the cell. Antibodies can be designed to bind to proteins with a very high level of specificity. That's what gives it the targeted portion. Then the whole thing gets taken up by the cell and broken down, which releases the chemotherapy part. Some sources will call this the 'payload' or the 'warhead.'  That's the part that's attached to the 'heat-seeking' part, and that's what causes the cell death," Kenneth Tham, PharmD, BCOP, clinical pharmacist in general oncology at the University of Washington Medicine and Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about antibody–drug conjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 28, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the mechanism of action of antibody–drug conjugates. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Antibody–Drug Conjugates Join the Best of Two Worlds Into One New Treatment Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer Oncology Nurses' Role in Translating Biomarker Testing Results The Pharmacist's Role in Combination Cancer Treatments ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin Fam-trastuzumab deruxtecan-nxki ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Other ONS resources: Antineoplastic Administration Huddle Card Biomarker Database Chemotherapy Huddle Card Monoclonal Antibodies Huddle Card Association of Cancer Care Centers (ACCC) antibody–drug conjugates page Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) National Cancer Institute cancer drugs page Network for Collaborative Oncology Development and Advancement (NCODA) clinical resource library ACCC/HOPA/NCODA/ONS Patient Education Sheets website To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The mechanism of action of the chemo itself depends on what agent or what 'warhead' is attached. Generally, [ADCs] have some kind of cytotoxic mechanism related to many of the chemotherapies that we use in practice, without attachment to the antibody. Some of them can be microtubule inhibitors, vinca alkaloids like vincristine. Some of them can be topoisomerase I (TOP1) inhibitors like irinotecan. Some can be alkylating agents that cause DNA breaks. So, again, looking back at the arsenal we have of cytotoxic chemo, these can all be incorporated into the ADCs." TS 5:54 "I want to talk about a case where the biomarker is being tested, but the biomarker isn't the target that you're looking for. One good case of this is a newer agent that was approved called datopotamab deruxtecan. The datopotamab portion is specific to a target called 'trophoblast cell surface antigen 2' (TROP2), which is expressed on the surface of many epithelial cancers. This agent was first approved in hormone receptor-positive, HER2-negative breast cancer, and received accelerated approval in patients with non-small cell lung cancer (NSCLC) with an EGFR mutation. ... The antibody looks for a target, TROP2. But in both of these cases—in the breast cancer and the NSCLC—you're testing for expression of different mutations or lack thereof. You're not looking for expression of TROP2. There's more research that needs to be done about the relationship between TROP2 expression and the presence or absence of these other biomarkers, but until we know more, we're actually testing for biomarkers that aren't the target of the ADC." TS 10:22 "There are common adverse advents to antibodies and chemo in general. Because we have both of these components, we want to watch out for the adverse effects of both of them. Antibodies, as with most proteins, can trigger an immune response or an infusion reaction. So, many ADCs can also cause hypersensitivity or infusion reactions. The rates of that are really variable and depend on the actual antibodies themselves. Then you have the cytotoxic component, the chemotherapy component, which has its own characteristic side effects. So, if we think of general chemo side effects—fatigue, nausea, bone marrow suppression, alopecia—these can [occur] with a lot of ADCs as well." TS 15:34 "The rate of ocular toxicity in [mirvetuximab soravtansine] is quite high. The manufacturer reports that this can occur in up to 60% of patients. With rates so high, the manufacturer recommends a preventive strategy. For this particular agent, [they] recommend patients have required eyecare. ... This ocular toxicity is something we do see in other ADCs that don't have the same target and don't necessarily have the same payload component. For example, tisotumab vedotin and again, datopotamab deruxtecan, can both cause ocular toxicities and both would have required ocular supportive care." TS 20:08 "Overall, I feel like the future is incredibly bright for these agents. There have only been around a dozen therapies approved by the U.S. Food and Drug Administration (FDA) despite this idea—the first agent came out in 2000. So, 25 years later, there are only around a dozen FDA-approved treatments. But there are so many more that are coming through the pipeline. And as we're discovering more biomarkers and developing more specialized antibodies, it's only natural that more ADCs will follow." TS 26:50

Welcome to OncLive On Air®! OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. In today's episode, we had the pleasure of speaking with Joshua Richter, MD, about the rationale and implications for the phase 1 CAMMA 1 study (NCT04910568), which is investigating the bispecific antibody cevostamab (RG6160; BFCR4350A) in patients with relapsed/refractory multiple myeloma. Dr Richter is an associate professor of medicine at The Tisch Cancer Institute and director of Multiple Myeloma at the Blavatnik Family Chelsea Medical Center at Mount Sinai in New York, New York. In our exclusive interview, Dr Richter discussed the rationale for targeting FcRH5 in the development of therapies for multiple myeloma, the evaluation of cevostamab-based combination strategies in patients with relapsed/refractory disease, and what the future may hold in this research arena. 

Most people are told: "If you have thyroid antibodies, you have Hashimoto's. If you don't, you don't." In this episode, Dr. Eric Balcavage, creator of the Adaptive Thyroid Model™, revisits that idea and shows why antibodies are only one piece of a much bigger picture. Discover how: ✅ Th1 and Th17 T-cells, CD8 T-cells, and low T-regs drive thyroid inflammation and tissue damage ✅ PAMPs (pathogen signals) and DAMPs (cell-danger signals) can bind to pattern-recognition receptors [PRRs] on thyroid cells, triggering cytokines and interferon activity ✅ Antibodies may confirm Hashimoto's, but their absence doesn't rule it out (seronegative Hashimoto's is real) ✅ Addressing the drivers of immune imbalance — gut permeability, sleep debt, oxidative stress, nutrient deficiencies — can help restore tolerance and thyroid function Dr. Balcavage breaks down the latest research on how inflammation starts inside the thyroid, why the body isn't "attacking" itself, and what a true recovery plan looks like.

In this bonus episode, Matt and Paul answer Patreon listener questions  on  various topics, including the role of AI in medicine, concerns about antibiotics and their impact on health, insomnia treatments, thyroid health, reflections on career burnout and more. They also share personal anecdotes and insights emphasizing the importance of continuous learning and adaptation in the medical field. Chapters 00:00 Exploring AI in Medicine 04:50 Cultural Shifts in Music Appreciation 10:16 Navigating Medical Questions and Antibiotics 14:57 Insomnia Medications and Sleep Hygiene 19:58 Thyroid Health and Selenium 24:59 Reflections on Career and Burnout 29:55 Closing Thoughts and Gratitude